Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 mitomycin C on the growth and liver metastasis of human colon cancer

Japanese Journal of Cancer Research

Volumn 92, Issue 6, 2001, Pages 688-695

  Ohta, M ^a   Konno, H ^a   Tanaka, T ^a   Baba, M ^a   Kamiya, K ^a   Oba, K ^a   Kaneko, T ^a   Syouji, T ^a   Igarashi, A ^a   Nakamura, S ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colon cancer; Matrix metalloproteinase inhibitor; Metastasis; Mitomycin C

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; DRUG VEHICLE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; MMI 166; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ER MP12; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COLON CANCER; CONTROLLED STUDY; DENSITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; METASTASIS INHIBITION; MICROVASCULATURE; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0034929463     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01149.x     Document Type: Article

References (41)

1. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
2. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
3. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to clinical application
4. Localization of messenger RNA for Mr 72 000 and 92 000 type IV collagenase in human skin cancer by in situ hybridization
5. Tumor invasion and metastasis-role of the extracellular matrix: Rhoads memorial award lecture
6. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma
7. Expression of matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
8. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
9. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteases
10. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a signal metalloproteinase capable of degrading basement membrane collagen
11. Type IV collagenase (MR 72 000) expression in human prostate: Benign and malignant tissue
12. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma
13. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells
14. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts
15. Interferon gamma induces cell cycle arrest and apoptosis in model of ovarian cancer: Enhancement of effect by batimastat
16. Control lymphatic and hematogenous metastasis of a rat mammary carcinoma by matrix metalloproteinase inhibitor batimastat
17. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice
18. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models
19. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
20. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
21. Inhibition of tumor growth by marimastat in human xenograft model of gastric cancer: Relationship with level of circulation CEA
22. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
23. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
24. Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice
25. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduce local invasion and metastasis of murine Lewis lung carcinoma
26. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
27. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites
28. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer
29. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor Marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term study
30. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers
31. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on Batimastat and Marimastat
32. Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody
33. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470
34. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice
35. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and Mitomycin C on the growth and liver metastasis of human colon cancer
36. Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro
37. Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer
38. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors
39. Combination therapy of vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft
40. Comparative pharmacokinetics of BAY 12-9566, a metallo-proteinase inhibitor, in healthy volunteers and cancer patients
41. Anti-angiogenetic activity of BAY12-9566 in human colon carcinoma HCT116 orthotopic model